Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis

Eur Heart J. 2018 May 14;39(19):1672-1686f. doi: 10.1093/eurheartj/ehy066.
No abstract available

Publication types

  • Consensus Development Conference

MeSH terms

  • Anticoagulants / pharmacokinetics
  • Anticoagulants / therapeutic use
  • Bariatric Surgery / adverse effects
  • Body Mass Index*
  • Cardiovascular Diseases / complications
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / pharmacokinetics
  • Fibrinolytic Agents / therapeutic use*
  • Hemorrhage / chemically induced
  • Humans
  • Nutrition Disorders / etiology
  • Obesity / complications
  • Obesity / surgery
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Platelet Aggregation Inhibitors / therapeutic use
  • Postoperative Complications
  • Risk Factors
  • Thrombosis / prevention & control*

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors